comms@paragonbiosci.com

58 items

October 19, 2018

Paragon Biosciences Announces $71.8 Million in New Investment for Portfolio Company Castle Creek Pharma
Paragon organizes new investment from Fidelity Management [...]
October 19, 2018

Crain’s Chicago Business: “Chicago-based Biotech Incubator Raises $71.8 Million”
October 19, 2019 – Paragon Biosciences CEO Jeff Aronin [...]
October 1, 2018

Jeff Aronin Named One of the 20 Most Influential Leaders in Healthcare for 2018
Paragon CEO Jeff Aronin Recognized by Insights Care [...]
August 21, 2018

Paragon Biosciences Announces Skyline Biosciences as the Newest Addition to Its Growing Portfolio of Companies
CHICAGO – August 21, 2018 – Paragon Biosciences [...]
August 14, 2018

Emalex Biosciences Acquires Psyadon Pharmaceuticals to Develop Novel Treatment for Pediatric Tourette Syndrome
CHICAGO – August 14, 2018 – Biopharmaceutical company [...]
August 9, 2018

Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex
Biopharmaceutical company currently evaluating diacerein 1% ointment (CCP-020) [...]
June 25, 2018

Castle Creek Pharmaceuticals Announces First Patient with Epidermolysis Bullosa Enrolled in Pharmacokinetics Study of Diacerein 1% Ointment
New multi-center Phase 1 study expected to [...]
May 16, 2018

Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa
PARSIPPANY, N.J., May 16, 2018 – Castle Creek [...]

Previous 678 Next